Market Report: Glimmer of hope for Synergy Health shareholders
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.There was a glimmer of hope yesterday for shareholders of Synergy Health, which might yet wrap up its takeover by Ohio-based Steris. The FTSE 250 company, which sterilises medical instruments for hospitals, agreed to a $1.9bn (£1.2bn) buyout last October but the US Federal Trade Commission revealed in May that it was looking to block the deal.
Yesterday, both groups pushed back their shareholder votes by a week to 2 October. Synergy said no decision had yet been made on the US watchdog’s request for a preliminary injunction. This was enough to send the share price up 40p to 1,550p.
After the anticlimactic end to last week’s trading, with no rise in US interest rates, there was a distinct feeling of déjà vu with the spotlight back on Greece and China.
Alexis Tsipras and his Syriza party secured another four years in power, while business optimism in China sank to its lowest since 2007.
That hurt mining shares, with Glencore retreating 7p to 119p, close to last week’s all-time lows, while Anglo American lost 25.1p to 694.9p.
News that Zurich Insurance turned its back on insurer RSA, down 106.2p to 403.3p, was the other notable patch of red on trading screens, but it was enough to restrict the FTSE 100 to a gain of just 4.6 points to 6,108.71.
Plumbing supplies group Wolseley, up 87p to 4,223p, was added to Credit Suisse’s list of top stocks with a new and improved 4,900p target.
Peroni brewer SABMiller, now a bid target of the US giant AB InBev, drifted 24.5p lower to 3,575.5p as RBC Capital asked questions about the deal. “We are not convinced that the potential acquisition of SABMiller would work culturally or strategically,” the broker said.
On the mid-cap index, Petra Diamonds, down 9.9p at 101.1p, lost its sparkle after big producer De Beers warned that the Chinese slowdown and a strong dollar was affecting its business.
An agreement with China’s Citic put a rocket under minnow Sable Mining Africa, which soared 0.75p or 142 per cent to 1.28p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments